Boris Winterhoff1, Habib Hamidi2, Chen Wang3, Kimberly R Kalli3, Brooke L Fridley4, Judy Dering2, Hsiao-Wang Chen2, William A Cliby5, He-Jing Wang6, Sean Dowdy5, Bobbie S Gostout5, Gary L Keeney5, Ellen L Goode3, Gottfried E Konecny7. 1. Department of Obstetrics/Gynecology & Women's Health, University of Minnesota, Minneapolis, MN, United States. 2. Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States. 3. Department of Health Sciences Research, Mayo Clinic, Rochester, MN, United States. 4. Department of Biostatistics, University of Kansas, Kansas City, KS, United States. 5. Department of Gynecologic Surgery, Mayo Clinic, Rochester, MN, United States. 6. Department of Biostatistics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States. 7. Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States. Electronic address: gkonecny@mednet.ucla.edu.
Abstract
BACKGROUND: It is unclear whether the transcriptional subtypes of high grade serous ovarian cancer (HGSOC) apply to high grade clear cell (HGCCOC) or high grade endometrioid ovarian cancer (HGEOC). We aim to delineate transcriptional profiles of HGCCOCs and HGEOCs. METHODS: We used Agilent microarrays to determine gene expression profiles of 276 well annotated ovarian cancers (OCs) including 37 HGCCOCs and 66 HGEOCs. We excluded low grade OCs as these are known to be distinct molecular entities. We applied the prespecified TCGA and CLOVAR gene signatures using consensus non-negative matrix factorization (NMF). RESULTS: We confirm the presence of four TCGA transcriptional subtypes and their significant prognostic relevance (p<0.001) across all three histological subtypes (HGSOC, HGCCOC and HGEOCs). However, we also demonstrate that 22/37 (59%) HGCCOCs and 30/67 (45%) HGEOCs form 2 additional separate clusters with distinct gene signatures. Importantly, of the HGCCOC and HGEOCs that clustered separately 62% and 65% were early stage (FIGO I/II), respectively. These finding were confirmed using the reduced CLOVAR gene set for classification where most early stage HGCCOCs and HGEOCs formed a distinct cluster of their own. When restricting the analysis to the four TCGA signatures (ssGSEA or NMF with CLOVAR genes) most early stage HGCCOCs and HGEOC were assigned to the differentiated subtype. CONCLUSIONS: Using transcriptional profiling the current study suggests that HGCCOCs and HGEOCs of advanced stage group together with HGSOCs. However, HGCCOCs and HGEOCs of early disease stages may have distinct transcriptional signatures similar to those seen in their low grade counterparts.
BACKGROUND: It is unclear whether the transcriptional subtypes of high grade serous ovarian cancer (HGSOC) apply to high grade clear cell (HGCCOC) or high grade endometrioid ovarian cancer (HGEOC). We aim to delineate transcriptional profiles of HGCCOCs and HGEOCs. METHODS: We used Agilent microarrays to determine gene expression profiles of 276 well annotated ovarian cancers (OCs) including 37 HGCCOCs and 66 HGEOCs. We excluded low grade OCs as these are known to be distinct molecular entities. We applied the prespecified TCGA and CLOVAR gene signatures using consensus non-negative matrix factorization (NMF). RESULTS: We confirm the presence of four TCGA transcriptional subtypes and their significant prognostic relevance (p<0.001) across all three histological subtypes (HGSOC, HGCCOC and HGEOCs). However, we also demonstrate that 22/37 (59%) HGCCOCs and 30/67 (45%) HGEOCs form 2 additional separate clusters with distinct gene signatures. Importantly, of the HGCCOC and HGEOCs that clustered separately 62% and 65% were early stage (FIGO I/II), respectively. These finding were confirmed using the reduced CLOVAR gene set for classification where most early stage HGCCOCs and HGEOCs formed a distinct cluster of their own. When restricting the analysis to the four TCGA signatures (ssGSEA or NMF with CLOVAR genes) most early stage HGCCOCs and HGEOC were assigned to the differentiated subtype. CONCLUSIONS: Using transcriptional profiling the current study suggests that HGCCOCs and HGEOCs of advanced stage group together with HGSOCs. However, HGCCOCs and HGEOCs of early disease stages may have distinct transcriptional signatures similar to those seen in their low grade counterparts.
Authors: Gottfried E Konecny; Chen Wang; Habib Hamidi; Boris Winterhoff; Kimberly R Kalli; Judy Dering; Charles Ginther; Hsiao-Wang Chen; Sean Dowdy; William Cliby; Bobbie Gostout; Karl C Podratz; Gary Keeney; He-Jing Wang; Lynn C Hartmann; Dennis J Slamon; Ellen L Goode Journal: J Natl Cancer Inst Date: 2014-09-30 Impact factor: 13.506
Authors: Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov Journal: Proc Natl Acad Sci U S A Date: 2005-09-30 Impact factor: 11.205
Authors: Roel G W Verhaak; Pablo Tamayo; Ji-Yeon Yang; Diana Hubbard; Hailei Zhang; Chad J Creighton; Sian Fereday; Michael Lawrence; Scott L Carter; Craig H Mermel; Aleksandar D Kostic; Dariush Etemadmoghadam; Gordon Saksena; Kristian Cibulskis; Sekhar Duraisamy; Keren Levanon; Carrie Sougnez; Aviad Tsherniak; Sebastian Gomez; Robert Onofrio; Stacey Gabriel; Lynda Chin; Nianxiang Zhang; Paul T Spellman; Yiqun Zhang; Rehan Akbani; Katherine A Hoadley; Ari Kahn; Martin Köbel; David Huntsman; Robert A Soslow; Anna Defazio; Michael J Birrer; Joe W Gray; John N Weinstein; David D Bowtell; Ronny Drapkin; Jill P Mesirov; Gad Getz; Douglas A Levine; Matthew Meyerson Journal: J Clin Invest Date: 2012-12-21 Impact factor: 14.808
Authors: Donald R Schwartz; Sharon L R Kardia; Kerby A Shedden; Rork Kuick; George Michailidis; Jeremy M G Taylor; David E Misek; Rong Wu; Yali Zhai; Danielle M Darrah; Heather Reed; Lora H Ellenson; Thomas J Giordano; Eric R Fearon; Samir M Hanash; Kathleen R Cho Journal: Cancer Res Date: 2002-08-15 Impact factor: 12.701
Authors: Rong Wu; Neali Hendrix-Lucas; Rork Kuick; Yali Zhai; Donald R Schwartz; Aytekin Akyol; Samir Hanash; David E Misek; Hidetaka Katabuchi; Bart O Williams; Eric R Fearon; Kathleen R Cho Journal: Cancer Cell Date: 2007-04 Impact factor: 31.743
Authors: Stefan Kommoss; Boris Winterhoff; Ann L Oberg; Gottfried E Konecny; Chen Wang; Shaun M Riska; Jian-Bing Fan; Matthew J Maurer; Craig April; Viji Shridhar; Friedrich Kommoss; Andreas du Bois; Felix Hilpert; Sven Mahner; Klaus Baumann; Willibald Schroeder; Alexander Burges; Ulrich Canzler; Jeremy Chien; Andrew C Embleton; Mahesh Parmar; Richard Kaplan; Timothy Perren; Lynn C Hartmann; Ellen L Goode; Sean C Dowdy; Jacobus Pfisterer Journal: Clin Cancer Res Date: 2017-02-03 Impact factor: 12.531
Authors: Alexia T Kedves; Scott Gleim; Xiaoyou Liang; Dennis M Bonal; Frederic Sigoillot; Fred Harbinski; Sneha Sanghavi; Christina Benander; Elizabeth George; Prafulla C Gokhale; Quang-De Nguyen; Paul T Kirschmeier; Robert J Distel; Jeremy Jenkins; Michael S Goldberg; William C Forrester Journal: J Clin Invest Date: 2017-11-13 Impact factor: 14.808
Authors: Boris Winterhoff; Stefan Kommoss; Florian Heitz; Gottfried E Konecny; Sean C Dowdy; Sally A Mullany; Tjoung-Won Park-Simon; Klaus Baumann; Felix Hilpert; Sara Brucker; Andreas du Bois; Willibald Schröder; Alexander Burges; Steven Shen; Jinhua Wang; Roshan Tourani; Sisi Ma; Jacobus Pfisterer; Constantin F Aliferis Journal: AMIA Annu Symp Proc Date: 2018-12-05
Authors: Mollie E Barnard; Alexander Pyden; Megan S Rice; Miguel Linares; Shelley S Tworoger; Brooke E Howitt; Emily E Meserve; Jonathan L Hecht Journal: Gynecol Oncol Date: 2018-07-09 Impact factor: 5.482
Authors: Robert L Hollis; John P Thomson; Barbara Stanley; Michael Churchman; Alison M Meynert; Tzyvia Rye; Clare Bartos; Yasushi Iida; Ian Croy; Melanie Mackean; Fiona Nussey; Aikou Okamoto; Colin A Semple; Charlie Gourley; C Simon Herrington Journal: Nat Commun Date: 2020-10-05 Impact factor: 14.919